UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Vermunt, L; Sikkes, SAM; van den Hout, A; Handels, R; Bos, I; van der Flier, WM; Kern, S; ... ICTUS/DSA study groups, .; + view all (2019) Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's and Dementia , 15 (7) pp. 888-898. 10.1016/j.jalz.2019.04.001. Green open access

[thumbnail of Zetterberg_AAM_Vermunt et al.pdf]
Preview
Text
Zetterberg_AAM_Vermunt et al.pdf - Accepted Version

Download (1MB) | Preview

Abstract

INTRODUCTION: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. // METHODS: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. // RESULTS: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. // DISCUSSION: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.

Type: Article
Title: Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.jalz.2019.04.001
Publisher version: https://doi.org/10.1016/j.jalz.2019.04.001
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: APOE, Alzheimer's disease, Clinical setting, Dementia, Disease duration, Multistate model, Preclinical, Prodromal, Progression
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10079199
Downloads since deposit
12,844Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item